Understand the source comparison
Cerebrolysin Men Over 40: Clinical vs Research Comparison
Acute stroke recovery 30–50 mL daily Intravenous 21 days NIHSS score, mRS, infarct volume High-dose short-term intervention for acute neuroprotection. Not applicable to healthy aging Vascular dementia trials 20–30 mL daily 20 days (repeated monthly) ADAS-cog,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Acute stroke recovery
- 30–50 mL daily
- Intravenous
- 21 days
- NIHSS score, mRS, infarct volume
- High-dose short-term intervention for acute neuroprotection. Not applicable to healthy aging
- Vascular dementia trials
- 20–30 mL daily
- 20 days (repeated monthly)
- ADAS-cog, MMSE, GDS
- Moderate-dose with monthly cycling. Targets established pathology, not prevention
- Mild cognitive impairment
- 10 mL 5×/week
- 4 weeks, 8-week washout
- Trail Making Test, Digit Span, subjective reports
- Evidence-based for men over 40 with measurable decline. Most relevant protocol for cognitive support
- Research/personal optimization
- 5–10 mL 5×/week
- IV or subcutaneous
- 4 weeks, 2–3 month washout
- Subjective cognition, neuroplasticity biomarkers
- Lower dose, structured cycling. Used by biohackers and longevity-focused researchers, limited RCT data in healthy populations
- The clinical protocols target diagnosed impairment with objective biomarkers. Research applications in healthy aging rely on subjective reports and exploratory endpoints. Men over 40 without diagnosed pathology typically fall into the fourth category. Using published mechanisms and dosing frameworks but without the regulatory oversight or diagnostic criteria that define clinical use. This isn't off-label in the traditional sense because cerebrolysin isn't FDA-approved for any indication. It's a research compound used under informed self-direction or clinical supervision outside standard-of-care pathways.